Patents by Inventor Rong-rong Zhu

Rong-rong Zhu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROSTAGLANDIN E2 BINDING PROTEINS AND USES THEREOF
    Publication number: 20140186377
    Abstract: The present invention encompasses prostaglandin E2 (PGE2) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin E2 and neutralize prostaglandin E2 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin E2 and for inhibiting prostaglandin E2 activity, e.g., in a human subject suffering from a disorder in which prostaglandin E2 activity is detrimental.
    Type: Application
    Filed: November 26, 2013
    Publication date: July 3, 2014
    Applicant: AbbVie, Inc.
    Inventors: Jijie Gu, Charles W. Hutchins, Rong-Rong Zhu, Jianwei Shen, Maria C. Harris, Eileen Belanger, Tariq Ghayur, Paul R. Hinton, Veronica M. Juan, John Mankovich, Junjian Liu
  • Prostaglandin E2 binding proteins and uses thereof
    Patent number: 8624002
    Abstract: The present invention encompasses prostaglandin E2 (PGE2) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin E2 and neutralize prostaglandin E2 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin E2 and for inhibiting prostaglandin E2 activity, e.g., in a human subject suffering from a disorder in which prostaglandin E2 activity is detrimental.
    Type: Grant
    Filed: July 8, 2009
    Date of Patent: January 7, 2014
    Assignee: AbbVie, Inc.
    Inventors: Jjijie Gu, Charles W. Hutchins, Rong-rong Zhu, Jianwei Shen, Maria C. Harris, Eileen Belanger, Anwar Murtaza, Edit Tarcsa, William B. Stine, Chung-ming Hsieh
  • Prostaglandin E2 Binding Proteins and Uses Thereof
    Publication number: 20100040537
    Abstract: The present invention encompasses prostaglandin E2 (PGE2) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin E2 and neutralize prostaglandin E2 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin E2 and for inhibiting prostaglandin E2 activity, e.g., in a human subject suffering from a disorder in which prostaglandin E2 activity is detrimental.
    Type: Application
    Filed: July 8, 2009
    Publication date: February 18, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: Jjijie Gu, Charles W. Hutchins, Rong-rong Zhu, Jianwei Shen, Maria C. Harris, Eileen Belanger, Anwar Murtaza, Edit Tarcsa, William B. Stine, Chung-ming Hsieh